Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin

被引:2
|
作者
Zhou, SY [1 ]
Starkov, A [1 ]
Froberg, MK [1 ]
Leino, RL [1 ]
Wallace, KB [1 ]
机构
[1] Univ Minnesota, Sch Med, Dept Biochem & Mol Biol, Toxicol Grad Program, Duluth, MN 55812 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interference with mitochondrial calcium regulation is proposed to be a primary causative event in the mechanism of doxorubicin-induced cardiotoxicity, We previously reported disruption of mitochondrial calcium homeostasis after chronic doxorubicin administration (Solen ei al, Toxicol, Appl, Pharmacol., 129: 214-222, 1994). The present study was designed to characterize the dose-dependent and cumulative interference with mitochondrial calcium regulation and to assess the reversibility of this functional lesion. Sprague Dawley rats were treated with 2 mg/kg/week doxorubicin s.c. for 4-8 weeks. With succinate as substrate, cardiac mitochondria isolated from rats after 4 weeks of treatment with doxorubicin expressed a lower calcium loading rapacity compared with control. This suppression of calcium loading capacity increased with successive doses to 8 weeks of treatment (P < 0.05) and persisted for 5 weeks after the last doxorubicin injection, and was corroborated by dose-dependent and irreversible histopathological changes, Preincubation of mitochondria with tamoxifen, DTT, or monobromobimane did not reverse the diminished calcium loading capacity caused by doxorubicin, In contrast, incubation with cyclosporin A abolished any discernible difference in mitochondrial calcium loading capacity between doxorubicin-treated and saline-treated rats. The decrease in cardiac mitochondrial calcium loading capacity was not attributable to bioenergetic changes in the electron transport chain, because the mitochondrial coupling efficiency was not altered by doxorubicin treatment. However, the ADP/ATP translocase content was significantly lower in mitochondria from rats that received 8 weeks of doxorubicin treatment. These data indicate that doxorubicin treatment in vivo causes a dose-dependent and irreversible decrease in mitochondrial calcium loading capacity. Suppression of adenine nucleotide translocase content may be a key factor altering the calcium-dependent regulation of the mitochondrial permeability transition pore, which may account for the cumulative and irreversible loss of myocardial function in patients receiving doxorubicin chemotherapy.
引用
收藏
页码:771 / 777
页数:7
相关论文
共 50 条
  • [21] Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction
    Hydock, David S.
    Lien, Chia-Ying
    Schneider, Carole M.
    Hayward, Reid
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2008, 40 (05): : 808 - 817
  • [22] Reduction of ER Stress Ameliorated Doxorubicin-Induced Cardiac Dysfunction
    Fu, Haiying
    Matsuzaki, Takashi
    Okuda, Keiji
    Yamato, Masaki
    Tsutida, Shota
    Araki, Ryo
    Minamino, Tetsuo
    Takata, Yasushi
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (10) : S159 - S159
  • [23] Attenuation of doxorubicin-induced cardiac injury by mitochondrial glutaredoxin 2
    Diotte, Nicole M.
    Xiong, Ye
    Gao, Jinping
    Chua, Balvin H. L.
    Ho, Ye-Shih
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2009, 1793 (02): : 427 - 438
  • [24] Exercise Training Attenuates Cardiac Mitochondrial Dysfunction And Oxidant Production Following Doxorubicin Treatment
    Kavazis, Andreas N.
    Smuder, Ashley J.
    Min, Kisuk
    Tuemer, Nihal
    Powers, Scott K.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2010, 42 (05): : 637 - 637
  • [25] Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy
    Li, LH
    Takemura, G
    Li, YW
    Miyata, S
    Esaki, M
    Okada, H
    Kanamori, H
    Khai, NC
    Maruyama, R
    Ogino, A
    Minatoguchi, S
    Fujiwara, T
    Fujiwara, H
    CIRCULATION, 2006, 113 (04) : 535 - 543
  • [26] Exercise training attenuates acute doxorubicin-induced cardiac dysfunction
    Chicco, AJ
    Schneider, CM
    Hayward, R
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 (02) : 182 - 189
  • [27] Cardiolipin nanodisks confer protection against doxorubicin-induced mitochondrial dysfunction
    Fox, Colin A.
    Romenskaia, Irina
    Dagda, Ruben K.
    Ryan, Robert O.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2022, 1864 (10):
  • [28] Doxorubicin-induced cognitive impairment and baroreflex dysfunction: a cumulative dose-dependent effect
    Amaro-Leal, A.
    Machado, F.
    Afonso, A. I.
    Rocha, I.
    Geraldes, V.
    ACTA PHYSIOLOGICA, 2022, 236 : 505 - 507
  • [29] ACETYLCHOLINE RECEPTOR AGONISTS ATTENUATE DOXORUBICIN-INDUCED CARDIAC DYSFUNCTION AND AUTONOMIC IMBALANCE VIA IMPROVING MITOCHONDRIAL FUNCTION IN RATS
    Prathumsap, Nanthip
    Ongnok, Benjamin
    Thawatchai, Khuanjing
    Arinno, Apiwan
    Maneechote, Chayodom
    Apaijai, Nattayaporn
    Chunchai, Titikorn
    Shinlapawittayatorn, Krekwit
    Arunsak, Busarin
    Jaiwongkam, Thidarat
    Kerdphoo, Sasiwan
    Chattipakorn, Siriporn
    Chattipakorn, Nipon
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3299 - 3299
  • [30] Sirt3 attenuates doxorubicin-induced cardiac hypertrophy and mitochondrial dysfunction via suppression of Bnip3
    Du, Qiong
    Zhu, Bin
    Zhai, Qing
    Yu, Bo
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (07): : 3360 - 3373